TW201808930A - 作為抗癌劑之雜環約束型三環磺醯胺 - Google Patents

作為抗癌劑之雜環約束型三環磺醯胺 Download PDF

Info

Publication number
TW201808930A
TW201808930A TW105129416A TW105129416A TW201808930A TW 201808930 A TW201808930 A TW 201808930A TW 105129416 A TW105129416 A TW 105129416A TW 105129416 A TW105129416 A TW 105129416A TW 201808930 A TW201808930 A TW 201808930A
Authority
TW
Taiwan
Prior art keywords
mmol
group
piperan
tetrahydro
compound according
Prior art date
Application number
TW105129416A
Other languages
English (en)
Chinese (zh)
Inventor
麥可 歐米爾
尼須 札維爾
Original Assignee
美國西奈山伊坎醫學院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國西奈山伊坎醫學院 filed Critical 美國西奈山伊坎醫學院
Publication of TW201808930A publication Critical patent/TW201808930A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW105129416A 2015-09-09 2016-09-09 作為抗癌劑之雜環約束型三環磺醯胺 TW201808930A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562216172P 2015-09-09 2015-09-09
US62/216,172 2015-09-09

Publications (1)

Publication Number Publication Date
TW201808930A true TW201808930A (zh) 2018-03-16

Family

ID=56936551

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105129416A TW201808930A (zh) 2015-09-09 2016-09-09 作為抗癌劑之雜環約束型三環磺醯胺

Country Status (8)

Country Link
US (1) US10759790B2 (enExample)
EP (1) EP3347355B1 (enExample)
JP (1) JP6955485B2 (enExample)
CN (1) CN108349961B (enExample)
AR (1) AR105975A1 (enExample)
CA (1) CA2997784A1 (enExample)
TW (1) TW201808930A (enExample)
WO (1) WO2017044569A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458916A (zh) 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
EP3116860B1 (en) 2014-03-11 2018-02-07 Icahn School of Medicine at Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
US10450282B2 (en) * 2015-08-06 2019-10-22 Icahn School Of Medicine At Mount Sinai Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2021150697A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
WO2021150700A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
CN112778257A (zh) * 2021-01-21 2021-05-11 香港科技大学 一种将糠醇氧化为二氢吡喃酮类衍生物的绿色方法
EP4288414A1 (en) * 2021-02-08 2023-12-13 Rappta Therapeutics Oy Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same
EP4543863A1 (en) * 2022-06-23 2025-04-30 University Of Ottawa Ferroptosis inhibitors and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634766A (en) 1983-10-31 1987-01-06 Merck Frosst Canada, Inc. 1,4-diaza-phenothiazines
GB8510680D0 (en) 1985-04-26 1985-06-05 Smith Kline French Lab Pyridine derivatives
US4882351A (en) 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
DE69431470T2 (de) 1993-07-26 2003-08-14 Eisai Co., Ltd. Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring
EP0881220A4 (en) 1996-02-15 1999-04-21 Mitsubishi Chem Corp DIARYLSULTAME DERIVATIVES
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
WO1999043683A1 (en) 1998-02-27 1999-09-02 Eisai Co., Ltd. Heterocycle-fused benzothiazine derivatives
MY120281A (en) 2000-09-20 2005-09-30 Schering Corp Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
JP4428053B2 (ja) 2002-02-05 2010-03-10 味の素株式会社 ガバペンチン若しくはプレガバリンおよびｎ型カルシウムチャンネル拮抗剤を含有する医薬組成物
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
AU2005318465A1 (en) 2004-12-21 2006-06-29 Devgen N.V. Compounds with Kv4 ion channel activity
IT1362675B (it) 2005-03-15 2009-06-25 Menarini Internat Operations Luxembourg Sa N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
BRPI0608469A2 (pt) 2005-04-22 2010-01-05 Alantos Pharmaceuticals Holding Inc inibidores de dipeptidil peptidase-iv
GB0508992D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008121859A1 (en) 2007-03-30 2008-10-09 Xenon Pharmaceuticals Inc. Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions
WO2012154678A1 (en) * 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic sulfonamide compounds and methods of making and using same
AU2012296528B2 (en) * 2011-08-16 2017-07-06 Icahn School Of Medicine At Mount Sinai Tricyclic compounds as anticancer agents
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102942562B (zh) 2012-12-05 2014-10-01 天津市斯芬克司药物研发有限公司 一种苯并咪唑衍生物及其制备方法和应用
CA2901493A1 (en) * 2013-02-19 2014-08-28 Icahn School Of Medicine At Mount Sinai Tricyclic heterocycles as anticancer agents
CN106458916A (zh) 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
EP3116860B1 (en) 2014-03-11 2018-02-07 Icahn School of Medicine at Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
US10450282B2 (en) 2015-08-06 2019-10-22 Icahn School Of Medicine At Mount Sinai Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols
WO2017044575A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2017044571A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
WO2017044572A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Ring constrained diarylamino sulfonamides as anti-cancer agents

Also Published As

Publication number Publication date
AR105975A1 (es) 2017-11-29
JP2018526419A (ja) 2018-09-13
EP3347355B1 (en) 2022-07-13
EP3347355A1 (en) 2018-07-18
CN108349961B (zh) 2022-02-18
JP6955485B2 (ja) 2021-10-27
HK1259348A1 (zh) 2019-11-29
US10759790B2 (en) 2020-09-01
US20180251456A1 (en) 2018-09-06
WO2017044569A1 (en) 2017-03-16
CA2997784A1 (en) 2017-03-16
CN108349961A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
TW201808930A (zh) 作為抗癌劑之雜環約束型三環磺醯胺
JP7584815B2 (ja) 抗腫瘍薬物における芳香族化合物及びその用途
TWI543961B (zh) Novel hydroxamic acid derivatives
JP6966425B2 (ja) 抗がん剤としての複素環式の限定された三環系スルホンアミド
CN105916855A (zh) 作为酪蛋白激酶1d/e抑制剂的取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物
JP2020532506A (ja) 化合物、組成物、及び、方法
WO2013033268A2 (en) Bivalent bromodomain ligands, and methods of using same
CN110267962A (zh) Magl抑制剂
CN106458936A (zh) 作为抗癌药的三环‑2‑氨基环烷醇衍生的磺酰胺
WO2017044575A1 (en) Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents
CN105008370B (zh) 作为cftr抑制剂的三环化合物
CN107922353A (zh) Ido抑制剂
EP3160965A1 (en) 3-substituted 2-amino-indole derivatives
WO2017044571A1 (en) Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
CN105026375A (zh) Ship1调节剂和与其相关的方法
CN118076610A (zh) 具有ent1抑制活性的大环化合物
KR20200083515A (ko) 2고리 설폰 및 설폭사이드, 및 이의 사용 방법
IL302922A (en) Methods and composition for kras modifications
KR20230166084A (ko) Abhd6 안타고니스트
WO2019129114A1 (zh) 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用
TW202220999A (zh) 作為造血前驅細胞激酶１（ｈｐｋ１）抑制劑的吲唑及其使用方法
HK1259348B (en) Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CN116332961A (zh) 取代的杂芳基化合物及其组合物和用途
TW202517241A (zh) 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN119192202A (zh) 含磷或含硫的大环吡唑并嘧啶类化合物及其用途